2007
DOI: 10.1016/j.urology.2007.06.356
|View full text |Cite
|
Sign up to set email alerts
|

MP-20.24: Tolterodine extended release (TER) and/or Tamsulosin (TAM) in men with lower urinary tract symptoms (LUTS) including overactive bladder (OAB): effects of prostate size

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2008
2008
2008
2008

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 0 publications
0
1
0
Order By: Relevance
“…One possible explanation for this discrepancy might be that men were required to meet symptom entry criteria for both OAB and BPH trials and might thus have constituted a study population different from that in most OAB or BPH trials, although not necessarily different from the general population of men with LUTS. In fact, two additional post hoc analyses in which men were stratified by baseline median prostate size [26], or baseline median serum PSA level [27], might suggest that the TIMES study population comprised both men with LUTS resulting primarily from a bladder condition and men with LUTS resulting primarily from prostatic enlargement that might or might not be accompanied by secondary bladder conditions [5,6,9]. These analyses found that tolterodine ER alone effectively improved storage LUTS in men who had smaller prostates (<29 mL) or lower PSA levels (<1.3 ng/mL) but not in men who had larger prostates (≥29 mL) or higher serum PSA levels (≥1.3 ng/mL) at baseline.…”
Section: Discussionmentioning
confidence: 99%
“…One possible explanation for this discrepancy might be that men were required to meet symptom entry criteria for both OAB and BPH trials and might thus have constituted a study population different from that in most OAB or BPH trials, although not necessarily different from the general population of men with LUTS. In fact, two additional post hoc analyses in which men were stratified by baseline median prostate size [26], or baseline median serum PSA level [27], might suggest that the TIMES study population comprised both men with LUTS resulting primarily from a bladder condition and men with LUTS resulting primarily from prostatic enlargement that might or might not be accompanied by secondary bladder conditions [5,6,9]. These analyses found that tolterodine ER alone effectively improved storage LUTS in men who had smaller prostates (<29 mL) or lower PSA levels (<1.3 ng/mL) but not in men who had larger prostates (≥29 mL) or higher serum PSA levels (≥1.3 ng/mL) at baseline.…”
Section: Discussionmentioning
confidence: 99%